Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.36 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987753 | 0.94 | TRPC3 (0.39) | MAPTLMNATP53USP30TRPC3 | |
| SCHEMBL22988174 | 0.94 | TRPC3 (0.39) | MAPTLMNATP53USP30TRPC3 | |
| SCHEMBL22987623 | 0.93 | RXFP1 (0.42) | MAPTLMNARXFP1TP53USP30 | |
| SCHEMBL22987919 | 0.92 | MAPT (0.39) | MAPTLMNARXFP1TP53USP30 | |
| SCHEMBL22987465 | 0.92 | TP53 (0.39) | MAPTLMNARXFP1TP53USP30 | |
| SCHEMBL22988052 | 0.91 | MAPT (0.42) | MAPTLMNARXFP1TP53USP30 | |
| SCHEMBL22987624 | 0.90 | USP30 (0.36) | MAPTLMNARXFP1TP53USP30 | |
| SCHEMBL22987627 | 0.89 | ADORA3 (0.40) | MAPTTP53TRPC3TRPC7 | |
| SCHEMBL22987521 | 0.88 | ADORA3 (0.35) | USP30TRPC3TRPC7ENPP2 | |
| SCHEMBL29646426 | 0.88 | ADORA3 (0.35) | USP30TRPC3TRPC7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | MAPT 4047/4885LMNA 2937/4885RXFP1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.